Karen Smith

Insider profile

Currently holds positions in Sucampo Pharmaceuticals Inc, Sangamo Therapeutics, Inc. and Antares Pharma Inc

Positions

Position Company Period
Director Sucampo Pharmaceuticals Inc July 15, 2017 -
Independent Director Sangamo Therapeutics, Inc. June 26, 2018 -
Independent Director Antares Pharma Inc March 4, 2019 -
Global Head of Research & Development and Chief Medical Officer Jazz Pharmaceuticals PLC April 1, 2015 - March 26, 2018
Karen Smith's trades of Aurinia Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
288.42
Quantity 33,486 +47.1%
Value US$1,095,524
Transaction date
Planned sale
Price
49.26
Quantity 97,125 +9.6%
Value US$4,375,594
Transaction date
Planned purchase
Price
143.63
Quantity 580 +4.5%
Value US$83,305
Transaction date
Planned purchase
Price
149.61
Quantity 557 +4.5%
Value US$83,335
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-11-12 2024-11-11
S Sale
43,526 +28.0%
14.47
US$1,372,196 		43,526 +28.0% 14.47 US$1,372,196
2021-04-05 2021-04-05
PlS Planned sale
33,486 +47.1%
288.42
US$1,095,524 		33,486 +47.1% 288.42 US$1,095,524
2021-04-05 2021-04-05
PlS Planned sale
97,125 +9.6%
49.26
US$4,375,594 		97,125 +9.6% 49.26 US$4,375,594
2016-07-13 2016-07-13
PP Planned purchase
580 +4.5%
143.63
US$83,305 		580 +4.5% 143.63 US$83,305
2016-06-15 2016-06-13
PP Planned purchase
557 +4.5%
149.61
US$83,335 		557 +4.5% 149.61 US$83,335